BTIG Research reiterated their buy rating on shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) in a research note released on Tuesday,Benzinga reports. The brokerage currently has a $58.00 target price on the stock.
AVTX has been the subject of several other reports. Wedbush decreased their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Mizuho increased their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. HC Wainwright decreased their price objective on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Wolfe Research initiated coverage on Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.67.
Check Out Our Latest Stock Report on Avalo Therapeutics
Avalo Therapeutics Stock Down 1.8%
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, equities analysts anticipate that Avalo Therapeutics will post -2.58 EPS for the current fiscal year.
Insider Buying and Selling at Avalo Therapeutics
In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the sale, the chief financial officer owned 8,880 shares of the company’s stock, valued at approximately $116,239.20. This trade represents a 48.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the sale, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 112,586 shares of company stock valued at $2,089,651. 4.46% of the stock is owned by company insiders.
Institutional Investors Weigh In On Avalo Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG lifted its holdings in Avalo Therapeutics by 956.9% in the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after acquiring an additional 432,608 shares during the period. Patient Square Capital LP acquired a new position in shares of Avalo Therapeutics during the 3rd quarter worth $1,271,000. Moody Aldrich Partners LLC acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth $2,419,000. Cantor Fitzgerald L. P. acquired a new position in shares of Avalo Therapeutics during the 3rd quarter worth $1,083,000. Finally, Nan Fung Trinity HK Ltd. acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth $3,432,000. Institutional investors and hedge funds own 87.06% of the company’s stock.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Featured Stories
- Five stocks we like better than Avalo Therapeutics
- Fox Captures The Living Room With $22B Roku Buy
- Could a Tesla-SpaceX Merger Be Closer Than Investors Think?
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
